Eli Lilly and Company is a leading American pharmaceutical firm headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company has grown into a global entity with operations in approximately 125 countries and a workforce of around 47,000 employees as of 2024 .(Wikipedia)
📈 Financial Performance
Q1 2025 Highlights:
-
Revenue: $12.73 billion (up 45% year-over-year)
-
Adjusted EPS: $3.34 (surpassing analyst expectations)
-
Net Income: $2.76 billion
-
Key Products:
-
Mounjaro (Type 2 diabetes): $3.84 billion in sales
-
Zepbound (obesity): $2.31 billion in sales (WSJ, Investopedia, Investor's Business Daily)
-
2024 Full-Year Results:
-
Revenue: $45.04 billion (32% increase from 2023)
-
Net Income: $10.59 billion
-
Adjusted EPS: $11.71 (Lilly Investor Relations)
2025 Outlook:
-
Projected Revenue: $58.0 to $61.0 billion
-
Adjusted EPS Guidance: $22.50 to $24.00 (Lilly Investor Relations)
💊 Product Portfolio & Pipeline
Eli Lilly's growth is significantly driven by its incretin-based therapies:(Lilly Investor Relations)
-
Mounjaro (tirzepatide): Approved for Type 2 diabetes, it's a major revenue contributor.
-
Zepbound: Approved for obesity treatment and, more recently, for moderate-to-severe obstructive sleep apnea in adults with obesity .(Lilly Investor Relations)
Other notable products include:
-
Omvoh: Approved for moderately to severely active Crohn's disease.
-
Kisunla: Approved in China for early symptomatic Alzheimer's disease.
-
Verzenio: Used in oncology treatments.(Lilly Investor Relations)
The company is also advancing its pipeline with acquisitions, such as the pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program .(Lilly Investor Relations)
⚠️ Challenges & Strategic Responses
Despite strong sales, Eli Lilly faces challenges:(Reuters)
-
Insurance Coverage: CVS Health plans to remove Zepbound from its reimbursement list starting July 1, favoring Novo Nordisk's Wegovy due to better pricing. This decision affects approximately 30 million insured individuals .
-
Profit Outlook: The company lowered its full-year profit forecast due to deal-related charges and external trade uncertainties, including potential tariffs .(Reuters)
In response, Eli Lilly is:
-
Investing in Manufacturing: Committing $27 billion to bolster U.S. manufacturing capabilities .
-
Advocating for Tax Incentives: CEO David Ricks supports a proposed tax bill aiming to establish a permanent 15% domestic production tax rate to encourage pharmaceutical manufacturing in the U.S. .(Reuters, WSJ)
Stock market information for Lilly(Eli) & Co (LLY)
- Lilly(Eli) & Co is a equity in the USA market.
- The price is 821.46 USD currently with a change of -1.17 USD (-0.00%) from the previous close.
- The latest trade time is Tuesday, May 6, 15:43:17 +0500.
Eli Lilly continues to demonstrate robust growth driven by its innovative therapies, particularly in the diabetes and obesity segments. While facing challenges in insurance coverage and profit forecasts, the company's strategic investments and product pipeline position it well for sustained success.(MarketWatch)